Evidence map›Paper›PMID 41244098›Full record

ArticleCase reports in hematology2025

Chronic Anaphylaxis With Indolent Systemic Mastocytosis: A Case Report.

Sarah Worth, Tracy I George, Daniel J Shaheen, Maria Roche, Pankit Vachhani

Registry-linked trialAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03731260 (A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03731260 phase2active not recruitingnot on this map

A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy

TypeinterventionalSponsorBlueprint Medicines CorporationRan2019 to 2027Enrolled251ConditionsIndolent Systemic MastocytosisArmsAvapritinib, Placebo
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sarah WorthDepartment of Pharmacy, University of Alabama, Birmingham, Alabama, USA.ORCID https://orcid.org/0000-0002-6451-4890
Tracy I GeorgeARUP Laboratories, Salt Lake City, Utah, USA.ORCID https://orcid.org/0000-0001-5478-7847
Daniel J ShaheenBlueprint Medicines Corporation, Cambridge, Massachusetts, USA.ORCID https://orcid.org/0009-0007-2799-6708
Maria RocheBlueprint Medicines Corporation, Cambridge, Massachusetts, USA.ORCID https://orcid.org/0009-0004-9608-2916
Pankit VachhaniDepartment of Medicine, Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA.ORCID https://orcid.org/0000-0001-9779-6217

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Systemic mastocytosis is a rare, clonal mast cell disease neoplasm driven by the Trial Registration: ClinicalTrials.gov identifier: NCT03731260.

Indexed as

allergyanaphylaxisavapritinibcase reportfulminant presentationimmunologyindolentmidostaurinsystemic mastocytosis

Identifiers

PMID41244098
PMCPMC12615035

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.